Healing With Venlafaxine After Injury (HELP)

Neck Pain Clinical Trial

— HELP  

Official title:

Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01716377
• Other study ID #: 104106
• Status: Completed
• Phase: Phase 2
• First received: October 25, 2012
• Last updated: April 12, 2017
• Start date: October 2012
• Est. completion date: September 2016

Study information

• Verified date: April 2017
• Source: Rhode Island Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Purpose: The purpose of this study is to demonstrate the potential efficacy of venlafaxine administration in reducing acute and chronic musculoskeletal pain in individuals presenting to the ED for evaluation after motor vehicle collision.

Participants: Participants will consist of 60 patients between the ages of 18-50 who present to the ED within 12 hours post-motor vehicle collision. Patients who report a neck pain score > 6 will be screened for further eligibility.

Procedures (methods): Using a placebo-controlled, randomized, double-blind trial design, 60 high risk patients will be randomized to venlafaxine vs. placebo in the ED. The ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed during serial short-term telephone follow-ups as well as more in-depth follow-ups at 6 weeks, 4 months, and 6 months post-MVC.

Description:

Results from both animal and human studies suggest that treatment with the serotonin-norepinephrine reuptake inhibitor (SNRIs) venlafaxine may reduce post-MVC pain. In addition, venlafaxine has been shown to be beneficial in reducing posttraumatic stress disorder (PTSD) symptoms, and in some patients PTSD symptoms may contribute to reinforcing pain persistence after trauma.

This phase IIB pilot trial will screen patients presenting to the ED after MVC for the presence of severe axial pain (>4 on a 0-10 numeric rating scale). Sixty of these "high risk" patients will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal axial pain will be assessed.

Results will be used to design a large-scale RCT assessing the efficacy of venlafaxine intervention in decreasing acute and persistent musculoskeletal pain in high-risk patients presenting to the ED after minor MVC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Between the ages of 18 and 59

• Presents to ED within 24 hours of MVC

• ED axial pain score greater than or equal to 4 (0-10 NRS)

• Clinically sober

• Willing to provide a blood sample

• Has a telephone

• Has regular access to Internet and an email address

• Able to speak and read English

• Permanent US citizen or has a green card

• Blood pressure reading(s) in ED that, when considered in the context of patient past and current history, in the investigator's judgment does not exceed acceptable level

Exclusion Criteria:

• Axial pain score greater than 0 in the past month (0-10 NRS)

• Clinically unstable

• Fracture (other than fracture of the phalanges)

• Substantial soft tissue injury

• Hepatic failure (acute or chronic)

• Renal failure (acute or chronic)

• Coronary artery disease, including previous MI, Angina, PCTA, etc.

• History of glaucoma

• Previous congestive heart failure

• History of seizure disorder

• History of mania or psychotic disorder

• History of suicidal ideation

• Prisoner

• History and behavior indicates, in the investigator's judgment, that the participant would likely be noncompliant with the study

• Any other condition that, in the investigator's judgment, would indicate that the patient in unsuitable for the study (e.g. might interfere with the study, confound interpretation, or endanger patient)

• Currently taking a monoamine oxidase inhibitor

• Currently taking medication with substantial interaction with venlafaxine, or which could confound interpretation of study results

• Breastfeeding

• If female, either not postmenopausal (having menses within past year), or, if childbearing potential, positive pregnancy test prior to randomization and not using a medically acceptable form of contraception

• Exceeds acceptable chronic daily opioid use prior to MVC

• Previously on venlafaxine

• Previous allergic reaction to venlafaxine

• Antidepressant use within 2 weeks of study start (4 week if Prozac)

Related Conditions & MeSH terms

• Neck Pain

Intervention

Drug:
• Venlafaxine
Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.

Locations

Country	Name	City	State
United States	University of Cincinnati	Cincinnati	Ohio
United States	Spectrum Health	Grand Rapids	Michigan
United States	University of Rochester Medical Center	Rochester	New York

Sponsors (5)

Lead Sponsor	Collaborator
Rhode Island Hospital	Baystate Medical Center, Mayday Fund, University of Cincinnati, University of North Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average neck pain	The primary outcome variable is average neck pain (0 - 10 numeric rating pain score recorded from patient) after study drug initiation through Day 31.	0-31 Days
Secondary	Chronic neck pain	The secondary outcome variable is average neck pain (0 - 10 numeric rating pain score recorded from patient) between study day 38 through 6 months.	Study day 38 through 6 months